In order to better define the therapeutic potential of the synthetic peptides shown here, that were useful to address the molecular mechanism of the IF1–OSCP binding in HeLa cells, their effects should be tested on other cell types and in in vivo cancer models. Here, ATP5PO is linked to cancer.